Compare VFC & PTCT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | VFC | PTCT |
|---|---|---|
| Founded | 1899 | 1998 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Apparel | Biotechnology: Pharmaceutical Preparations |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 6.6B | 6.5B |
| IPO Year | 1994 | 2006 |
| Metric | VFC | PTCT |
|---|---|---|
| Price | $17.10 | $76.93 |
| Analyst Decision | Hold | Buy |
| Analyst Count | 18 | 17 |
| Target Price | $18.24 | ★ $80.65 |
| AVG Volume (30 Days) | ★ 5.8M | 1.5M |
| Earning Date | 05-20-2026 | 05-07-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | 233.33 | ★ 264.48 |
| EPS | ★ 0.64 | N/A |
| Revenue | ★ $10,488,556,000.00 | $264,734,000.00 |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | $2.06 | $17.70 |
| P/E Ratio | $25.83 | ★ N/A |
| Revenue Growth | N/A | ★ 36.19 |
| 52 Week Low | $11.11 | $43.18 |
| 52 Week High | $22.27 | $90.87 |
| Indicator | VFC | PTCT |
|---|---|---|
| Relative Strength Index (RSI) | 49.91 | 43.24 |
| Support Level | $15.81 | $74.45 |
| Resistance Level | $16.94 | $79.67 |
| Average True Range (ATR) | 0.55 | 3.27 |
| MACD | 0.03 | -1.01 |
| Stochastic Oscillator | 65.88 | 4.47 |
VF designs, produces, and distributes branded apparel, footwear, and accessories. Its apparel categories are active, outdoor, and work. Its portfolio of 10 brands includes Vans, The North Face, Timberland, and Altra. VF markets its products in the Americas, Europe, and Asia-Pacific through wholesale sales to retailers, e-commerce, and branded stores owned by the company and partners. Tracing its roots to 1899, the company has evolved through many brand acquisitions and divestitures.
PTC Therapeutics Inc is a biopharmaceutical company that discovers, develops and commercializes clinically differentiated medicines that provide benefits to children and adults living with rare disorders. Its diversified therapeutic portfolio that includes several commercial products and product candidates in various stages of development, including discovery, research and clinical stages, focused on the development of new treatments for multiple therapeutic areas for rare diseases relating to neurology and metabolism. The company views its operations and manages its business in one operating segment: life science, which is focused on the discovery, development and commercialization of the company's clinically differentiated medicines that provide benefits to patients with rare disorders.